Wijaya, JohnsonBakri, SyakibDonosepoetro, Marsetio2013-10-232013-10-232010-05Wijaya Johnson, Bakri Syakib, Donosepoetro Marsetio. Correlation between F2-Isoprostane with stromal cell-derived factor-1 (SDF-1) and endothelial progenitor cell in nonhypertensive and hypertensive patients. Medical Journal of Indonesia. 2010 May; 19(2): 109-114.http://imsear.searo.who.int/handle/123456789/148930diseases. On the other hand, hypertension is related with excess angiotensin II which would lead to oxidative stress. In this study, we investigated the correlation between F2-Isoprostane (as marker of oxidative stress) with Stromal Cell-Derived Factor-1 (SDF-1) and CD34 viable in non hypertension and hypertension subjects. Methods This was a cross sectional study conducted on 54 nonhypertension and 64 hypertension subjects visiting Prodia laboratory, Jakarta. F2-Isoprostane (as marker of oxidative stress) and SDF-1 (a strmal cell growth factor) were measured by ELISA method, and CD34 viable (marker of progenitor cell) was measured by fl ow cytometry. Results F2-Isoprostane concentration was higher in hypertensive subjects compared to nonhypertensive subjects, although statistically non signifi ant (mean + SD: 0.13 ± 0.120 vs 0.10 ± 0.16; ρg/mL; p = 0.091). SDF-1 concentration was signifi cantly higher in hypertensive subjects compare to nonhypertensive subjects (2821.63 ± 281.94 vs 2623.04 ± 356.28 ρg/mL; P < 0.05). CD34 viable level was signifi cantly lower in hypertensive subjects compare to nonhypertensive subjects (1.9 ± 0.9 /μL vs 2.7 ± 1.7; P < 0.05). F2-Isoprostane had negative correlation with CD34 viable in circulation (r = 0.022, p < 0.05) but no correlation with SDF-1 (p > 0.05). Conclusions F2-Isoprostane was higher, but CD34 was lower, in hypertensive subjects compared to nonhypertensive. It seems that high F2-Isoprostane impaired the CD34 viable level as shown by negative correlation between F2- Isoprostane and CD34.enendothelial progenitor cellF2-IsoprostanhypertensionSDF-1HypertensionEndothelial Progenitor CellsF2-IsoprostanesArticle